The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies can result in inefficient heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, mitochondrial ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis; increased expression of ALAS1 by environmental factors contributes to the pathology of acute hepatic porphyria (AHP). Conversely, siRNA-mediated silencing (e.g., Givlaari®) reduces ALAS1 expression and the toxic accumulation of 5-ALA and PBG, validating ALAS1 as a clinical target for AHP. Recently, we identified a class of small molecules that rapidly promote ALAS1 degradation. One of these compounds, ONC201 (dordaviprone, Modeyso®), is an orally available small molecule recently approved by the FDA for the treatment of glioma. We previously showed that ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). In this study, we demonstrate that ALAS1 is robustly degraded in hepatic and erythroleukemia models in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA and PBG formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies suggest that ClpP agonists are effective small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.